Alliance for Pandemic Preparedness

December 21, 2020

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020

Category:

Topic:

Keywords (Tags):

The Advisory Committee on Immunization Practices issued an interim recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19 on December 19, 2020. Vaccination with the Moderna COVID-19 vaccine consists of 2 doses administered intramuscularly 4 weeks apart. Vaccine efficacy after 2 doses was 94.1% in preventing symptomatic, laboratory-confirmed COVID-19 among persons without evidence of previous SARS-CoV-2 infection. Evidence for the vaccine was primarily informed by one large, randomized, double-blind, placebo-controlled Phase III clinical trial that enrolled approximately 30,000 participants. 

Oliver et al. (Dec 20, 2020). The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm695152e1